$BHAC
Focus Impact BH3 Acquisition Co

2022 Q4 Form 10-K Financial Statement

#000119312523087706 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $675.9K $2.123M $14.40M
YoY Change -85.26%
Operating Profit $2.123M
YoY Change
Interest Expense $1.878M $9.875M $15.23K
YoY Change -113.05% 64738.21%
% of Operating Profit 465.19%
Other Income/Expense, Net $0.00 $0.00 $1.958M
YoY Change -100.0% -100.0%
Pretax Income $1.202M $7.753M -$12.43M
YoY Change -109.7% -162.39%
Income Tax $86.23K $100.0K $0.00
% Of Pretax Income 7.17% 1.29%
Net Earnings $1.116M $7.666M -$12.43M
YoY Change -109.0% -161.69%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.05 $0.28 -$983.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.72K $13.72K $1.131M
YoY Change -98.79% -98.79%
Cash & Equivalents $13.72K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00 $571.0K
YoY Change -100.0% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.72K $13.72K $1.702M
YoY Change -99.19% -99.19%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $51.34M $51.34M $232.3M
YoY Change -77.9% -77.9%
Other Assets
YoY Change
Total Long-Term Assets $51.34M $51.34M $232.3M
YoY Change -77.9% -77.9%
TOTAL ASSETS
Total Short-Term Assets $13.72K $13.72K $1.702M
Total Long-Term Assets $51.34M $51.34M $232.3M
Total Assets $51.35M $51.35M $234.0M
YoY Change -78.05% -78.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $88.01K
YoY Change
Accrued Expenses $0.00 $5.000K
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $300.0K $300.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.509M $2.509M $8.964M
YoY Change -72.01% -72.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.050M $8.050M $8.050M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $8.050M $8.050M $0.00
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.509M $2.509M $8.964M
Total Long-Term Liabilities $8.050M $8.050M $0.00
Total Liabilities $10.56M $10.56M $17.01M
YoY Change -37.94% -37.94%
SHAREHOLDERS EQUITY
Retained Earnings -$9.332M
YoY Change -28.37%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.331M $40.79M $217.0M
YoY Change
Total Liabilities & Shareholders Equity $51.35M $51.35M $234.0M
YoY Change -78.05% -78.05%

Cashflow Statement

Concept 2022 Q4 2022 2021
OPERATING ACTIVITIES
Net Income $1.116M $7.666M -$12.43M
YoY Change -109.0% -161.69%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.007M -$1.557M -$1.128M
YoY Change 4.95% 37.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $184.2M $184.0M -$232.3M
YoY Change -179.29% -179.2%
Cash From Investing Activities $184.2M $184.0M -$232.3M
YoY Change -179.29% -179.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $183.8M $25.00K
YoY Change 735276.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -183.5M -183.5M 234.6M
YoY Change -178.31% -178.25%
NET CHANGE
Cash From Operating Activities -1.007M -1.557M -1.128M
Cash From Investing Activities 184.2M 184.0M -232.3M
Cash From Financing Activities -183.5M -183.5M 234.6M
Net Change In Cash -352.0K -1.117M 1.131M
YoY Change -131.15% -198.79%
FREE CASH FLOW
Cash From Operating Activities -$1.007M -$1.557M -$1.128M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001851612
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40868
CY2022 dei Entity Registrant Name
EntityRegistrantName
CRIXUS BH3 ACQUISITION COMPANY
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2249068
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
819 NE 2nd Avenue
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Lauderdale
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33304
CY2022 dei City Area Code
CityAreaCode
954
CY2022 dei Local Phone Number
LocalPhoneNumber
416-3140
CY2022 dei Security12b Title
Security12bTitle
Class A common stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
BHAC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
241100000
CY2021Q4 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Net Derivative Asset Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants
CY2022 dei Auditor Firm
AuditorFirmId
248
CY2022 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2022Q4 us-gaap Cash
Cash
13715
CY2021Q4 us-gaap Cash
Cash
1131162
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
570994
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13715
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1702156
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
51340014
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
232284770
CY2022Q4 us-gaap Assets
Assets
51353729
CY2021Q4 us-gaap Assets
Assets
233986926
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
86230
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
CY2022Q4 bhacu Derivative Warrant Liability
DerivativeWarrantLiability
2122940
CY2021Q4 bhacu Derivative Warrant Liability
DerivativeWarrantLiability
8959173
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
300000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2509170
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8964173
CY2022Q4 bhacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
8050000
CY2021Q4 bhacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
8050000
CY2022Q4 us-gaap Liabilities
Liabilities
10559170
CY2021Q4 us-gaap Liabilities
Liabilities
17014173
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
50125920
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
230000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9331936
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13027822
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-9331361
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-13027247
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51353729
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233986926
CY2022 bhacu Formation And Operating Costs
FormationAndOperatingCosts
-2122772
bhacu Formation And Operating Costs
FormationAndOperatingCosts
-562177
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
2122772
us-gaap Operating Income Loss
OperatingIncomeLoss
562177
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Gain Loss On Investments
GainLossOnInvestments
-15230
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
3038631
us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6836233
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14400827
CY2022 bhacu Offering Costs Allocated To Public Warrants
OfferingCostsAllocatedToPublicWarrants
0
bhacu Offering Costs Allocated To Public Warrants
OfferingCostsAllocatedToPublicWarrants
1396078
CY2022 us-gaap Other Operating Income
OtherOperatingIncome
9874864
us-gaap Other Operating Income
OtherOperatingIncome
12989519
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7752982
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12427342
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
86230
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
7665862
us-gaap Net Income Loss
NetIncomeLoss
12427342
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
bhacu Sale Of Units Net Of Underwriting Discount Offering Costs And Warrant Liabilities
SaleOfUnitsNetOfUnderwritingDiscountOfferingCostsAndWarrantLiabilities
23000000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204520411
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-230000000
us-gaap Net Income Loss
NetIncomeLoss
12427342
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-13027247
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
3969976
CY2022 us-gaap Net Income Loss
NetIncomeLoss
7665862
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-9331361
CY2022 us-gaap Net Income Loss
NetIncomeLoss
7665862
us-gaap Net Income Loss
NetIncomeLoss
12427342
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Gain Loss On Investments
GainLossOnInvestments
-15230
CY2022 us-gaap Interest Income Money Market Deposits
InterestIncomeMoneyMarketDeposits
3038631
us-gaap Interest Income Money Market Deposits
InterestIncomeMoneyMarketDeposits
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6836233
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14400827
CY2022 bhacu Offering Costs Allocated To Public Warrants
OfferingCostsAllocatedToPublicWarrants
0
bhacu Offering Costs Allocated To Public Warrants
OfferingCostsAllocatedToPublicWarrants
1396078
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-570994
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
570994
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5000
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
86230
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1556778
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1128171
CY2022 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
232300000
CY2022 bhacu Maturities Of Marketable Securities In Trust Account
MaturitiesOfMarketableSecuritiesInTrustAccount
700391261
bhacu Maturities Of Marketable Securities In Trust Account
MaturitiesOfMarketableSecuritiesInTrustAccount
0
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
748934935
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
232527061
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
183983387
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232300000
CY2022 bhacu Proceeds From Sale Of Units Net Of Underwriting Discounts Paid
ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountsPaid
0
bhacu Proceeds From Sale Of Units Net Of Underwriting Discounts Paid
ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountsPaid
225400000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
9600000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
465667
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
300000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
145000
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-145000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
183844056
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-183544056
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234559333
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1117447
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1131162
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1131162
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13715
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1131162
CY2022 bhacu Deferred Underwriting Fee Payable Incurred But Not Yet Paid
DeferredUnderwritingFeePayableIncurredButNotYetPaid
0
bhacu Deferred Underwriting Fee Payable Incurred But Not Yet Paid
DeferredUnderwritingFeePayableIncurredButNotYetPaid
8050000
CY2022 us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
9276147
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10762592
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10762592
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 bhacu Percentage Of Ownership Of The Common Stock Issued And Outstanding
PercentageOfOwnershipOfTheCommonStockIssuedAndOutstanding
0.20
CY2022Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
3482975
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the derivative warrant liability. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates. </div></div></div>
CY2022Q4 us-gaap Cash
Cash
13715
CY2021Q4 us-gaap Cash
Cash
1131162
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
51300000
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
232300000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts or investment accounts in a financial institution, which at times, may exceed the Federal Depository Insurance Coverage<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div>250,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company has not experienced losses on these accounts.</div></div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
7665862
us-gaap Net Income Loss
NetIncomeLoss
12427342
CY2022 bhacu Deemed Dividend
DeemedDividend
-3969976
bhacu Deemed Dividend
DeemedDividend
-37127388
CY2022 bhacu Adjusted Net Income Loss
AdjustedNetIncomeLoss
3695886
bhacu Adjusted Net Income Loss
AdjustedNetIncomeLoss
-24700046
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
100000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 bhacu Transaction Cost
TransactionCost
22400000
CY2022 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
12700000
CY2022 bhacu Other Offering Costs.
OtherOfferingCosts.
500000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
8759346
CY2022 bhacu Number Of Days Within Which Securities Registration Shall Be Effective
NumberOfDaysWithinWhichSecuritiesRegistrationShallBeEffective
P60D
CY2022 bhacu Number Of Days After The Closing Of The Initial Business Combination Within Which The Securities Shall Be Filed
NumberOfDaysAfterTheClosingOfTheInitialBusinessCombinationWithinWhichTheSecuritiesShallBeFiled
P20D
CY2022Q4 us-gaap Share Price
SharePrice
18

Files In Submission

Name View Source Status
bhacu-20221231_cal.xml Edgar Link unprocessable
bhacu-20221231_lab.xml Edgar Link unprocessable
0001193125-23-087706-index-headers.html Edgar Link pending
0001193125-23-087706-index.html Edgar Link pending
0001193125-23-087706.txt Edgar Link pending
0001193125-23-087706-xbrl.zip Edgar Link pending
bhacu-20221231.xsd Edgar Link pending
d624110d10k.htm Edgar Link pending
d624110dex311.htm Edgar Link pending
d624110dex312.htm Edgar Link pending
d624110dex313.htm Edgar Link pending
d624110dex321.htm Edgar Link pending
d624110dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
bhacu-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bhacu-20221231_pre.xml Edgar Link unprocessable
d624110d10k_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending